Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PI3K-IN-1 (Voxtalisib Analogue) 是 PI3K 抑制剂,PI3K-IN-1(25 μM) 能够阻断 PI3K/Akt 信号通路。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 427 | 现货 | ||
2 mg | ¥ 616 | 现货 | ||
5 mg | ¥ 947 | 现货 | ||
10 mg | ¥ 1,660 | 现货 | ||
25 mg | ¥ 2,890 | 现货 | ||
50 mg | ¥ 4,330 | 现货 | ||
100 mg | ¥ 6,170 | 现货 | ||
500 mg | ¥ 12,600 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,290 | 现货 |
产品描述 | PI3K-IN-1 (Voxtalisib Analogue) is a dual inhibitor of mTOR/PI3K, mostly for p110γ , also inhibits DNA-PK and mTOR. |
靶点活性 | PI3Kγ:9 nM, PI3Kα:39 nM, DNA-PK:150 nM, PI3Kβ:113 nM, PI3Kδ:43 nM |
体外活性 | 在GBM 39-luc细胞植入的裸鼠中,口服XL765能够抑制肿瘤细胞的生长,同时提高存活率.在BxPC-3异种移植物小鼠模型中,XL765(30 mg / kg)与氯喹(50 mg / kg)联用,能够抑制肿瘤细胞生长. |
体内活性 | XL765对于I类PI3K有抑制作用,对于对于p110α(IC50=39 nM),p110β(IC50=113 nM),p110γ(IC50=9 nM)和p110δ(IC50=43 nM)。XL765通过显着抑制mTOR靶点S6,S6K和4EBP1的磷酸化,对mTOR(IC50 = 157 nM)产生抑制作用。在MIAPaCa-2细胞中,XL765处理后,产生自噬体积累。 |
激酶实验 | Radioligand Binding Assays: Each tube in the A3 AR competitive binding assay contains 100 μL of membrane suspension (20 μg of protein), 50 μL of [125I]4-amino-3-iodobenzyl)adenosine-5′-N-methyluronamide (0.5 nM), and 50 μL of increasing concentrations of the test ligands in Tris-HCl buffer (50 mM, pH 7.4) containing 10 mM MgCl2 and 1 mM EDTA. Nonspecific binding is determined using 10 mM 5′-N-ethylcarboxamidoadenosine in the buffer. The mixtures are incubated at 25°C for 60 min. Binding reactions are terminated by filtration through Whatman GF/B filters under reduced pressure using a MT-24 cell harvester. Filters are washed three times with 9 mL of ice-cold buffer. Radioactivity is determined using a Beckman γ-counter, and the percent inhibition is calculated. |
细胞实验 | Cells are treated with XL765 24 hours after plating and harvested for apoptosis or autophagy assays at 24, 48, or 72 hours after XL765 treatment. Apoptosis is determined by total percentage of annexin V-positive cells by fluorescence-activated cell sorting (FACS). Acidic vesicular organelles (AVOs) are detected in XL765-treated cells by vital staining with acridine orange. The degree of AVO formation is expressed as fold increase of acridine orange fluorescence intensity (FL3) in XL765-treated cells versus control cells. (Only for Reference) |
别名 | Voxtalisib Analogue, Voxtalisib (SAR245409, XL765) Analogue, XL765, SAR245409 |
分子量 | 599.66 |
分子式 | C31H29N5O6S |
CAS No. | 1349796-36-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mg/mL (16.7 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.6676 mL | 8.3381 mL | 16.6761 mL | 41.6903 mL |
5 mM | 0.3335 mL | 1.6676 mL | 3.3352 mL | 8.3381 mL | |
10 mM | 0.1668 mL | 0.8338 mL | 1.6676 mL | 4.169 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PI3K-IN-1 1349796-36-6 DNA Damage/DNA Repair PI3K/Akt/mTOR signaling DNA-PK PI3K Phosphoinositide 3-kinase muscle XL-147 derivative 1 cancer PI-3K-IN-1 SRC SAR 245409 XL-765 fibrosis Voxtalisib Analogue inhibit Voxtalisib (SAR245409, XL765) Analogue extraocular thyroid PI3K IN 1 Inhibitor XL765 SAR-245409 ophthalmopathy SAR245409 XL 765 PI3KIN1 gene inhibitor